JCR Pharmaceuticals Co., Ltd. (TYO:4552)

JCR Pharmaceuticals Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	9,661	14,007	13,196	18,756	13,278	30,733
Short-Term Investments	-	-	-	-	-	244
Cash & Short-Term Investments	9,661	14,007	13,196	18,756	13,278	30,977
Cash Growth	-26.70%	6.15%	-29.64%	41.26%	-57.14%	17.96%
Receivables	15,687	14,162	12,236	14,934	11,137	15,585
Inventory	24,464	24,041	22,187	20,933	18,514	14,636
Other Current Assets	3,938	3,866	3,868	2,958	4,873	990
Total Current Assets	53,750	56,076	51,487	57,581	47,802	62,188
Property, Plant & Equipment	38,951	39,244	37,104	30,040	32,681	26,782
Long-Term Investments	11,186	8,852	10,442	9,819	9,443	2,769
Other Intangible Assets	2,512	2,596	2,960	3,496	3,652	2,960
Long-Term Deferred Tax Assets	-	2,466	2,853	1,288	1,357	2,433
Other Long-Term Assets	1	2	3	2	2	2
Total Assets	106,400	109,236	104,849	102,226	94,937	97,134

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	671	523	590	890	1,563	1,324
Accrued Expenses	1,955	1,261	1,216	1,130	1,088	1,004
Short-Term Debt	42,092	38,092	23,005	8,950	16,800	15,150
Current Portion of Long-Term Debt	-	3,600	3,050	-	500	-
Current Income Taxes Payable	-	3,403	2,792	4,402	2,836	11,104
Other Current Liabilities	4,645	1,256	13,030	14,763	12,975	13,472
Total Current Liabilities	49,363	48,135	43,683	30,135	35,762	42,054
Long-Term Debt	11,850	12,200	12,050	14,350	5,500	2,950
Pension & Post-Retirement Benefits	941	914	966	903	924	870
Other Long-Term Liabilities	616	631	418	364	339	173
Total Liabilities	62,770	61,880	57,117	45,752	42,525	46,047

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	9,061	9,061	9,061	9,061	9,061	9,061
Additional Paid-In Capital	10,388	10,378	10,392	10,384	10,384	10,994
Retained Earnings	28,096	31,226	31,490	37,278	34,273	33,241
Treasury Stock	-4,946	-4,969	-5,066	-2,963	-2,978	-3,600
Comprehensive Income & Other	616	1,243	1,463	2,417	1,421	1,186
Total Common Equity	43,215	46,939	47,340	56,177	52,161	50,882
Minority Interest	415	417	392	297	251	205
Shareholders' Equity	43,630	47,356	47,732	56,474	52,412	51,087
Total Liabilities & Equity	106,400	109,236	104,849	102,226	94,937	97,134

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	53,942	53,892	38,105	23,300	22,800	18,100
Net Cash (Debt)	-44,281	-39,885	-24,909	-4,544	-9,522	12,877
Net Cash Growth	-	-	-	-	-	57.81%
Net Cash Per Share	-362.80	-326.90	-201.16	-36.24	-76.27	103.67
Filing Date Shares Outstanding	122.03	122.02	121.84	124.8	124.78	123.76
Total Common Shares Outstanding	122.03	121.99	121.84	124.8	124.78	123.76
Working Capital	4,387	7,941	7,804	27,446	12,040	20,134
Book Value Per Share	354.14	384.77	388.56	450.12	418.04	411.14
Tangible Book Value	40,703	44,343	44,380	52,681	48,509	47,922
Tangible Book Value Per Share	333.55	363.49	364.26	422.11	388.77	387.23

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error